ZA964373B - A pharmaceutical composition for treating lukemia - Google Patents

A pharmaceutical composition for treating lukemia

Info

Publication number
ZA964373B
ZA964373B ZA964373A ZA964373A ZA964373B ZA 964373 B ZA964373 B ZA 964373B ZA 964373 A ZA964373 A ZA 964373A ZA 964373 A ZA964373 A ZA 964373A ZA 964373 B ZA964373 B ZA 964373B
Authority
ZA
South Africa
Prior art keywords
lukemia
treating
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
ZA964373A
Other languages
English (en)
Inventor
James B Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of ZA964373B publication Critical patent/ZA964373B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ZA964373A 1995-06-07 1996-05-29 A pharmaceutical composition for treating lukemia ZA964373B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47381795A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ZA964373B true ZA964373B (en) 1996-09-02

Family

ID=23881113

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA964373A ZA964373B (en) 1995-06-07 1996-05-29 A pharmaceutical composition for treating lukemia

Country Status (17)

Country Link
EP (1) EP0831816A1 (zh)
JP (1) JPH11506732A (zh)
KR (1) KR19990022617A (zh)
CN (1) CN1186433A (zh)
AR (1) AR003137A1 (zh)
AU (1) AU717382B2 (zh)
BR (1) BR9608730A (zh)
CA (1) CA2223435A1 (zh)
CZ (1) CZ391197A3 (zh)
HU (1) HUP9802634A3 (zh)
IL (1) IL118424A0 (zh)
NO (1) NO975660L (zh)
PL (1) PL324026A1 (zh)
SK (1) SK168697A3 (zh)
TR (1) TR199701536T1 (zh)
WO (1) WO1996040122A1 (zh)
ZA (1) ZA964373B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) * 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL134354C (zh) * 1963-05-23
FR2155888A1 (en) * 1971-10-13 1973-05-25 Agot Aime Solid anthelmintic composn - for more economical treatment of ruminants
NZ305784A (en) * 1995-04-12 2001-03-30 Procter & Gamble Benzimidazole containing medicaments for treating cancers, tumors and viral infections

Also Published As

Publication number Publication date
AR003137A1 (es) 1998-07-08
NO975660L (no) 1998-02-09
AU5802096A (en) 1996-12-30
JPH11506732A (ja) 1999-06-15
BR9608730A (pt) 1999-06-29
HUP9802634A2 (hu) 1999-03-29
EP0831816A1 (en) 1998-04-01
IL118424A0 (en) 1996-09-12
CZ391197A3 (cs) 1998-05-13
TR199701536T1 (xx) 1998-02-21
HUP9802634A3 (en) 1999-05-28
KR19990022617A (ko) 1999-03-25
AU717382B2 (en) 2000-03-23
CN1186433A (zh) 1998-07-01
PL324026A1 (en) 1998-05-11
SK168697A3 (en) 1998-12-02
CA2223435A1 (en) 1996-12-19
WO1996040122A1 (en) 1996-12-19
NO975660D0 (no) 1997-12-05

Similar Documents

Publication Publication Date Title
IL117237A0 (en) Pharmaceutical composition for piperidinoalkanol compounds
HU9601698D0 (en) Pharmaceutical composition
EP0850057A4 (en) PHARMACEUTICAL COMPOSITIONS
ZA964373B (en) A pharmaceutical composition for treating lukemia
GB9519667D0 (en) Pharmaceutical composition
ZA962214B (en) Pharmaceutical composition
ZA963590B (en) Pharmaceutical composition
ZA961051B (en) Pharmaceutical composition
ZA9610426B (en) Pharmaceutical composition
ZA964193B (en) Pharmaceutical composition
SG47206A1 (en) Pharmaceutical compounds
AU7295696A (en) Pharmaceutical composition for treating osteoporosis
HUP9602822A2 (en) Pharmaceutical composition
ZA963591B (en) Pharmaceutical composition
ZA95736B (en) Pharmaceutical composition
ZA963388B (en) A pharmaceutical composition
HUP9602732A2 (en) Pharmaceutical composition comprising lanperisone
ZA961389B (en) Pharmaceutical composition for piperidinoalkanol compounds
SI0812195T1 (en) Pharmaceutical composition for piperidinoalkanol compounds
GB9506273D0 (en) Pharmaceutical compounds
GB9526437D0 (en) Pharmaceutical compounds
GB9511166D0 (en) Pharmaceutical compounds
GB9502811D0 (en) Pharmaceutical compounds
GB9522132D0 (en) Pharmaceutical compounds
GB9517867D0 (en) Pharmaceutical compounds